A study of Roche's Gazyva has raised the prospect of a first approved therapy for primary membranous nephropathy (pMN), a rare autoimmune kidney disorder. The phase 3 MAJESTY trial of anti-CD20 ...
Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in primary progressive multiple sclerosis (PPMS), revealing that it was at least as effective as its ...
Everymum on MSN
What are screens doing to your baby’s brain?
If you knew something you did regularly for your toddler could delay their development, actually change the physiology of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results